INIZIA IL black FRIDAY 3 |15% su tutto con il coupon 15alcubo | SCOPRI di più

Customer care
  • Dompé Levotuss Syrup 10 sachets 60mg / 10ml -42%

Dompé Levotuss Syrup 10 sachets 60mg / 10ml

5.79€ 9.90€
  • Purchase 3 items for 5.67€ each
  • Purchase 4 items for 5.56€ each
  • Purchase 5 items for 5.44€ each



Syrup in sachets






Sucrose, methyl-para-hydroxybenzoate, propyl-para-hydroxybenzoate, citric acid monohydrate, sodium hydroxide, cherry flavor, purified water.



Symptomatic cough therapy.



Hypersensitivity to the active ingredient or to any of the excipients; the administration of the drug should be avoided in patients with bronchorrhea and with reduced mucociliary function (Kar tagener's syndrome, ciliary dyskinesia); pregnancy and breastfeeding; do not add to children under the age of 2 years.



Adults and children over 30 kg: one sachet containing 10 ml of syrup up to 3 times a day at intervals of at least 6 hours.
Treatment should be continued until the cough disappears.
However, if after 2 weeks of therapy the cough should still be present, it is advisable to stop the treatment and seek advice from your doctor.
In fact, cough is a symptom and the causal pathology should be studied and treated.
Open the sachet following the dashed line and swallow the contents.
Pediatric population: do not add children to children under the age of 2 years.



No special precautions for storage.



The observation that the pharmacokinetic profiles of levodropropizin are not markedly altered in the elderly suggests that dose corrections or changes in intervals between administrations may not be required in the third age.
In any case, in light of the evidence that the sensitivity to various drugs is impaired in the elderly, specific caution should be used when levodropropizin is added to elderly patients.
Caution is advised in patients with severe renal failure (creatinine clearance below 35 ml / min).
Caution is advised even when simultaneously taking sedative drugs in particularly sensitive individuals.
This medicinal product contains 4 g of sucrose per dose (10 ml): patients with rare hereditary problems of fructose-intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine.
To be taken into consideration for administration to subjects suffering from diabetes mellitus.
The medicine contains methyl para-hydroxybenzoate and propyl p ara-hydroxybenzoate, known for the possibility of causing hives.
In general, para-hydroxybenzoates can cause delayed reactions, contact dermatitis and rarely immediate reactions with hives and bronchospasm.
The antitussive drugs are symptomatic and should only be used pending the diagnosis of the underlying cause and / or the effect of the underlying pathology therapy.
In the absence of information on the effect of food intake on the absorption of the drug, it is advisable to take the drug between meals.
Levotuss syrup does not contain gluten; therefore it can be administered to patients suffering from celiac disease.



Animal pharmacology studies have shown that levodropropizin does not enhance the pharmacological effect of active substances on the central nervous system (eg
benzodiazepines, alcohol, phenytoin, imipramine).
In animals, the product does not modify the activity of anticoagulants such as warfarin and does not even interfere with the hypoglycemic action of insulin.
In human pharmacology studies the association with benzodiazepine does not change the EEG framework.
However, caution should be exercised when simultaneously taking sedative drugs in particularly sensitive individuals.
From clinical studies there was no interaction with drugs used in the treatment of br oncopulmonary diseases such as beta2-agonists, methylxanthines and derivatives, corticost heroids, antibiotics, mucoregulators and antihistamines.



During treatment with levodropropizin palpation, tachycardia, nausea, vomiting, diarrhea, erythema may occur.
Reactions reported as a series are urticaria and anaphylactic reaction.
Most of the reactions that occur as a result of taking evodropropizin are non-serious and the symptoms have resolved with suspension of therapy and, in some cases, with specific drug treatment.
The adverse reactions found (whose frequency cannot be defined on the basis of the available data) are the following: Eye disorders: mydriasis, bilateral blindness.
Immune system disorders: allergic and anaphylactoid reactions, eyelid edema, angioneurotic edema, urticaria.
Psychiatric disorders: nervousness, abuse, alteration of personality or disorder of the person.
Nervous system disorders: syncope, dizziness, vertigo, t remori, paresthesia, tonic-clonic convulsion and attack of small but le, hypoglycemic coma.
Cardiac disorders: palpitations, tachycardia, atrial bigeminism.
Vascular disorders: hypotension.
Resp iratory, thoracic and mediastinal disorders: dyspnoea, cough, edema of the respiratory tract.
Gastrointestinal disorders: gastric pain, abdominal pain, nausea, vomiting, diarrhea.
Hepatobiliary disorders: static cole hepatitis.
Skin and subcutaneous tissue disorders: urticaria, and rash, rash, itching, angioedema, skin reactions, glossitis and aphthous stomatitis, epidermolysis.
Musculoskeletal and connective tissue disorders: weakness of the lower limbs.
Pathologies and systems and conditions related to the site of administration: general sere's disease, generalized edema, asthenia.
Pediatric population: a case of somnolence, hypotonia and vomiting was reported in a neonate after taking levodropropizin from the nursing mother.
The symptoms appeared after feeding and resolved spontaneously by suspending breastfeeding for some breastfeeds.



Studies of teratogenesis, reproduction and fertility as well as those of peri and post-natal revealed no specific toxic effects.
All avia, since in animal toxicological studies at a dose of 24 mg / kg a slight delay in body weight gain and growth was observed and since levodropropizine is able to overcome the placental barrier in the rat , the use of the drug is contraindicated in women who intend to become or are already pregnant as its safety in use is not documented.
Studies in the rat indicate that the drug is found in breast milk up to 8 hours after the action.
Therefore the use of the drug during breastfeeding is contraindicated.


Format 10 sachets 60mg / 10ml